Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
-
Right, left and centre
An article featuring expert commentary from ICON's Gretchen Goller on the importance of including patients at every stage of drug development.
-
Innovation in oncology drug development: A focus on patient benefits
An article by ICON's Dr. Brian Huber that examines how innovation, from the development of targeted therapies to a revolution in clinical trial designs, puts an emphasis on patient centricity.
-
A pathway to recovery
An opinion article from ICON's Chief Medical Officer, Kristen Buck on the role of Chief Medical Officers.
-
Treatment options for Clostridioides difficile
This thought leadership article explores the increase in antimicrobial-resistant infections such as C diff due to the high volume of patients being treated in hosipitals for COVID-19.
This article is taken from European Biopharmaceutical Review October 2020, pages 12-14. Samedan Ltd.
-
Decentralised trials – aided by tech – could boost clinical research
A Pharmaphorum article which considers how bringing clinical trials to patients – rather than the reverse – could be the key to improving recruitment into studies and making them faster, cheaper and more likely to succeed.
-
Adapting for the future of oncology
ICON experts Andreas Dreps and Martin Lachs share their thoughts on the future of cancer research and the importance of staying adaptive in PharmaPhorum's 'Future of Oncology 2020' magazine.
-
Navigating complexity in oncology cell and gene therapy clinical trials
This article featured in ClinicalOmics 'Insider's guide to precision medicine 2020' (pages 48 & 49) considers how cell and gene therapies are playing an increasingly important role in treating oncology patients.
-
-
An overview on rare disease research
ICON's Tim Clark and Will Maier examine the key clinical, regulatory, and commercial challenges associated with the development of therapies for the treatment of rare diseases.
